Skip to content
Screener

Total Liabilities at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$10.02B+21.0%
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
$7.12B+11.6%
EyePoint, Inc. logo
EyePoint, Inc.EYPT
$61.78M+12.0%
Regenxbio logo
RegenxbioRGNX
$314.85M-14.3%
KLR
Kalaris TherapeuticsKLRS
$41.25M+5.2%
Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
$1.66B-28.5%

Other financials

Income statement

See full
Revenue$3.0M+21,664%
Operating income-$73.6M-37.3%
Net income-$68.8M-43.3%
EPS (diluted)-$1.01-17.4%

Balance sheet

See full
Cash & equivalents$72.5M-45.7%
Total debt$20.5M-13.9%
Total equity$451.8M-3.8%
Total assets$512.9M-0.5%

Cash flow

See full
Operating cash flow-$68.1M-42.6%
CapEx--100%
Free cash flow-$68.1M-40.8%

Valuation

See full
Market cap$561.97M+119%
Enterprise value$510.02M+152%
P/S6.4×-7,758×

Profitability

See full
Operating margin-220.1%-110pp
Net margin-174,314.2%-62,763pp
FCF margin-154,209.2%-53,057pp

Returns & leverage

See full
Return on equity-45.4%+29.8pp
Debt / equity0.0×
Current ratio9.3×-3.0×

Where this comes from

Reported directly by 4D Molecular Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:Liabilities.

The source filing: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:13 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-211939
Line itemMarch 31,2026December 31,2025
Derivative liability370358
Operating lease liabilities, long-term portion15,04915,821
Other liabilities121138
Total liabilities61,06961,047
Commitments and contingencies (Note 8)
Stockholders’ equity
Preferred stock, $0.0001 par value, 10,000,000 shares authorized at March 31, 2026 and December 31, 2025; no shares issued and outstanding at March 31, 2026 and December 31, 2025
Common stock, $0.0001 par value, 300,000,000 shares authorized at March 31, 2026 and December 31, 2025; 52,271,648 and 57,607,874 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively56

Item 1. Condensed Financial Statements (Unaudited)

FAQ

What is 4D Molecular Therapeutics's total liabilities?
4D Molecular Therapeutics (FDMT) reported total liabilities of $61.07M in Q1 2026.
How has 4D Molecular Therapeutics's total liabilities changed year-over-year?
4D Molecular Therapeutics's total liabilities increased by 32.7% year-over-year, from $46.01M to $61.07M.
What is the long-term trend for 4D Molecular Therapeutics's total liabilities?
Over 5 years (2020 to 2025), 4D Molecular Therapeutics's total liabilities has grown at a 13.8% compound annual growth rate (CAGR), from $31.94M to $61.05M.
What does total liabilities mean?
The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.

Ask your AI about 4D Molecular Therapeutics's total liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude